Opdivo, Yervoy combination approved to treat malignant pleural mesothelioma
Combination immunotherapy treatment approved in the EU for first-line treatment of adults with unresectable MPM
Read More
Tag: malignant pleural mesothelioma
PIM status for Boehringer’s mesothelioma drug
Boehringer Ingelheim’s nintedanib has been designated a Promising Innovative Medicine for the treatment of malignant pleural mesothelioma (MPM) by the UK Medicine and Healthcare Products Regulatory Agency.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
